After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.

Researchers will use the funds to identify molecular signatures linked to different disease subtypes and test drugs on brain organoids.

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.